查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1404796

美国流感诊断市场规模、份额和趋势分析报告：按测试类型、最终用途和细分市场预测，2023-2030 年

U.S. Influenza Diagnostics Market Size, Share & Trends Analysis Report By Test Type (RIDT, RT-PCR, Cell Culture, Others), By End-use (Hospitals, POCT, Laboratories), And Segment Forecasts, 2023 - 2030
出版日期: | 出版商: Grand View Research | 英文 80 Pages | 商品交期: 2-10个工作天内

价格

美国流感诊断市场的成长与趋势：

Grand View Research, Inc.最新报告显示，到2030年，美国流感诊断市场规模预计将达到2.829亿美元，复合年增长率为5.9%。

市场的主要驱动因素包括疾病盛行率上升、老年人口增加以及流感高风险族群，如儿童、孕妇和患有各种慢性病的免疫抑制患者。

美国流感盛行率的上升预计将推动市场成长。根据CDC资料，2018年10月和2018年11月流感发生率相对较低，但2018年12月有所上升，并保持较高水平，直到2019年2月。甲型流感在美国东南部流行。 2018-2019流感检体期间，共检测了536,301份实验室检体，其中54,381份呈阳性，其中甲型流感52,028检体，乙型流感检体。这些事实表明，流感疫情正在上升，对诊断产品的需求增加。

此外，儿童、孕妇、慢性病免疫抑制患者和医护人员感染流感病毒的风险较高。例如，2018-2019 年 CDC 报告了 28 例儿童死亡，显示疾病发生率增加。根据美国疾病管制与预防中心 (CDC) 的数据，2018-2019 年，有 1,654 名 65 岁以上的人被诊断出患有流感。由于其免疫抑制状态，该族群容易感染流感和其他可能导致併发症的感染疾病。因此，透过家庭护理检测套组促进及时诊断预计将在预测期内进一步推动市场成长。

RDIT 由于其易于获得和易于使用，有利于快速诊断，因此在 2022 年占据了最大的市场占有率。此外，主要参与企业正在参与各种无机和有机策略开发，以扩大其现有产品系列併扩大地理范围。例如，2018 年，Quidel 公司获得了 FDA 510(k) 许可，用于快速诊断 A 型和 B 型流感的 CLIA 豁免 QuickVue A+B 型流感检测。此检测有助于透过患者的鼻咽和鼻拭子快速检测 B&A 型流感抗原。

由于流感疫情加剧，2022年医院将占据最大的市场占有率。由于主要企业提供技术先进的产品，POCT 成为成长最快的细分市场之一。例如，2016年，Becton, Dickinson, and Company推出了新型无线BD Veritor Plus系统，这是一种用于检测B&A病毒亚型的快速诊断设备。该产品用于医院、诊所和实验室。 BD Veritor Plus 系统由 BD 云端连线解决方案组成，可让使用者安全地将资料传输到电子健康记录。预计这些因素将对预测期内的市场潜力产生正面影响。

美国流感诊断市场报告亮点

  • RIDT的商业性可用性和快速的交付时间是其庞大市场占有率的主要因素。
  • RT-PCR领域在2022年占了21.8%的市占率。与细胞培养相比，RT-PCR 可以快速提供结果，从 2 分钟到不到 2 小时。
  • 美国流感诊断医院市场在2022年占据最大市场占有率，但预计随着POCT的出现而逐渐放缓。

目录

第一章调查方法和范围

第 2 章执行摘要

第 3 章美国流感诊断市场变数、趋势与范围

  • 市场体系展望
    • 母市场展望
    • 相关/附随市场展望
  • 普及和成长前景图
  • 市场动态
    • 市场驱动因素分析
    • 市场抑制因素分析
  • 美国流感诊断市场分析工具
    • 产业分析-波特五力分析
    • PESTEL分析

第四章美国流感诊断市场：测试类型估计和趋势分析

  • 美国流感诊断市场：重点
  • 美国流感诊断市场：2022 年和 2030 年测试类型趋势和市场占有率分析
  • RIDT
  • RT-PCR
  • 细胞培养
  • 其他的

第五章美国流感诊断市场：最终用途估计与趋势分析

  • 美国流感诊断市场：重点
  • 美国流感诊断市场：2022 年和 2030 年最终用途趋势和市场占有率分析
  • 医院
  • POCT
  • 实验室

第六章美国流感诊断市场：竞争形势

  • 主要市场参与企业的最新趋势和影响分析
  • 市场参与企业分类
    • 3M
    • Abbott
    • BD
    • Meridian Bioscience
    • Quidel Corporation
    • F. Hoffmann-La Roche Ltd
    • SA Scientific Ltd.
    • SEKISUI Diagnostics
    • Thermo Fisher Scientific Inc.
Product Code: GVR-3-68038-788-9

U.S. Influenza Diagnostics Market Growth & Trends:

The U.S. influenza diagnostics market size is expected to reach USD 282.9 million by the year 2030 growing at a CAGR of 5.9% according to a new report by Grand View Research, Inc. Key drivers of the market include rising disease prevalence, increase in geriatric population and high-risk population for influenza such as children, pregnant women and immunosuppressed patients suffering from various chronic diseases.

The rise in the prevalence of the flu in the U.S. is expected to boost market growth. Data from CDC indicates that flu incidence was relatively low in the months of October 2018 and November 2018, however, rise in the number of cases was witnessed in December 2018 and remained high until February 2019. Influenza A was dominant in the southeastern part of the U.S. During 2018-2019 flu season, 536,301 specimens were tested in laboratories out of which 54,381 tested positive, among which 52,028 were of influenza A and 2,353 of influenza B. These facts are indicative of the rising prevalence of the flu, necessitating increasing demand for diagnostic products.

Additionally, individuals with a high risk of contracting the influenza virus consist of children, pregnant women, immunosuppressed patients suffering from chronic diseases and healthcare workers. For instance, 28 pediatric deaths have been reported by the CDC in 2018-2019 indicative of the rising disease incidence. According to the CDC in 2018-2019, 1654 individuals aged 65 years of age and above were diagnosed with flu. Owing to their immunosuppressed state, this population group is more susceptible to flu and other infectious diseases causing complications. Thus, timely diagnosis facilitated by home care testing kits is further anticipated to fuel the market growth during the forecast period.

RDITs held the largest market share in 2022 as they are easily available and are user-friendly facilitating rapid diagnosis. In addition, key participants are engaged in various inorganic and organic strategic developments to expand their existing product portfolios and geographic expansion. For instance, in 2018, Quidel Corporation received 510(k) FDA clearance for their CLIA waived QuickVue Influenza A+B assay to be used for the rapid diagnosis of influenza A & B. This assay facilitates rapid detection of influenza B & A antigens by nasopharyngeal and nasal swab from patients.

Hospitals held the largest market share in 2022 due to the rise in prevalence of flu. POCT is one of the fastest-growing segments due to technologically advanced products offered by leading players. For instance, in 2016, Becton, Dickinson, and Company launched a new wireless BD Veritor Plus System which is a rapid diagnostic device for the detection of B & A virus subtypes. This product serves hospitals, clinics, and laboratories. BD Veritor Plus System consists of BD cloud connectivity solution that allows users to transfer data securely to an electronic medical record. These factors are thus anticipated to positively impact market potential during the forecast period.

U.S. Influenza Diagnostics Market Report Highlights:

  • Commercial availability of RIDTs and quick turnaround times are major factors that attribute to its large market share.
  • The RT-PCR segment held a significant share of 21.8% of the market in 2022. It delivers results faster in comparison to cell culture, ranging from 2 minutes to less than 2 hours.
  • The hospitals market for U.S. influenza diagnostics held the largest market share in 2022 but is expected to gradually slow down with the advent of POCT.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Test type
    • 1.1.2. End use
    • 1.1.3. Country scope
    • 1.1.4. Estimates and forecast timeline
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased database
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources
    • 1.3.4. Primary research
    • 1.3.5. Details of primary research
  • 1.4. Information or Data Analysis
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Test type outlook
    • 2.2.2. End use outlook
    • 2.2.3. Country outlook
  • 2.3. Competitive Insights

Chapter 3. U.S. Influenza Diagnostics Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Market Dynamics
    • 3.3.1. Market driver analysis
    • 3.3.2. Market restraint analysis
  • 3.4. U.S. Influenza Diagnostics Market Analysis Tools
    • 3.4.1. Industry Analysis - Porter's Five Forces
      • 3.4.1.1. Supplier power
      • 3.4.1.2. Buyer power
      • 3.4.1.3. Substitution threat
      • 3.4.1.4. Threat of new entrant
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Technological landscape
      • 3.4.2.3. Economic landscape

Chapter 4. U.S. Influenza Diagnostics Market: Test Type Estimates & Trend Analysis

  • 4.1. U.S. Influenza Diagnostics Market: Key Takeaways
  • 4.2. U.S. Influenza Diagnostics Market: Test Type Movement & Market Share Analysis, 2022 & 2030
  • 4.3. RIDT
    • 4.3.1. RIDT market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.4. RT-PCR
    • 4.4.1. RT-PCR market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.5. Cell Culture
    • 4.5.1. Cell culture market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.6. Others
    • 4.6.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 5. U.S. Influenza Diagnostics Market: End-use Estimates & Trend Analysis

  • 5.1. U.S. Influenza Diagnostics Market: Key Takeaways
  • 5.2. U.S. Influenza Diagnostics Market: End-use Movement & Market Share Analysis, 2022 & 2030
  • 5.3. Hospitals
    • 5.3.1. Hospitals market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.4. POCT
    • 5.4.1. POCT market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.5. Laboratories
    • 5.5.1. Laboratories market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 6. U.S. Influenza Diagnostics Market: Competitive Landscape

  • 6.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 6.2. Market Participant Categorization
    • 6.2.1. 3M
      • 6.2.1.1. Company overview
      • 6.2.1.2. Financial performance
      • 6.2.1.3. Product benchmarking
      • 6.2.1.4. Strategic initiatives
    • 6.2.2. Abbott
      • 6.2.2.1. Company overview
      • 6.2.2.2. Financial performance
      • 6.2.2.3. Product benchmarking
      • 6.2.2.4. Strategic initiatives
    • 6.2.3. BD
      • 6.2.3.1. Company overview
      • 6.2.3.2. Financial performance
      • 6.2.3.3. Product benchmarking
      • 6.2.3.4. Strategic initiatives
    • 6.2.4. Meridian Bioscience
      • 6.2.4.1. Company overview
      • 6.2.4.2. Financial performance
      • 6.2.4.3. Product benchmarking
      • 6.2.4.4. Strategic initiatives
    • 6.2.5. Quidel Corporation
      • 6.2.5.1. Company overview
      • 6.2.5.2. Financial performance
      • 6.2.5.3. Product benchmarking
      • 6.2.5.4. Strategic initiatives
    • 6.2.6. F. Hoffmann-La Roche Ltd
      • 6.2.6.1. Company overview
      • 6.2.6.2. Financial performance
      • 6.2.6.3. Product benchmarking
      • 6.2.6.4. Strategic initiatives
    • 6.2.7. SA Scientific Ltd.
      • 6.2.7.1. Company overview
      • 6.2.7.2. Financial performance
      • 6.2.7.3. Product benchmarking
      • 6.2.7.4. Strategic initiatives
    • 6.2.8. SEKISUI Diagnostics
      • 6.2.8.1. Company overview
      • 6.2.8.2. Financial performance
      • 6.2.8.3. Product benchmarking
      • 6.2.8.4. Strategic initiatives
    • 6.2.9. Thermo Fisher Scientific Inc.
      • 6.2.9.1. Company overview
      • 6.2.9.2. Financial performance
      • 6.2.9.3. Product benchmarking
      • 6.2.9.4. Strategic initiatives

List of Tables

  • Table 1 List of Abbreviations
  • Table 2 U.S. influenza diagnostics market, by test type, 2018 - 2030 (USD Million)
  • Table 3 U.S. influenza diagnostics market, by end-use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 U.S. influenza diagnostics: Market outlook
  • Fig. 9 U.S. influenza diagnostics: Competitive insights
  • Fig. 10 Parent market outlook
  • Fig. 11 Related/ancillary market outlook
  • Fig. 12 Penetration and growth prospect mapping
  • Fig. 13 U.S. influenza diagnostics market driver impact
  • Fig. 14 U.S. influenza diagnostics market restraint impact
  • Fig. 15 U.S. influenza diagnostics market strategic initiatives analysis
  • Fig. 16 U.S. influenza diagnostics market: Test type movement analysis
  • Fig. 17 U.S. influenza diagnostics market: Test type outlook and key takeaways
  • Fig. 18 RIDT market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 19 RT-PCR market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 20 Cell culture market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 21 Others market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 22 U.S. influenza diagnostics market: End use movement analysis
  • Fig. 23 U.S. influenza diagnostics market: End use outlook and key takeaways
  • Fig. 24 Hospitals market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 25 POCT market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 26 Laboratories market estimates and forecasts, 2018 - 2030 (USD Million)